News Channels

11 Oct 2019 Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
11 Oct 2019 MolMed informs on its decision to withdraw the Conditional Marketing Authorization of Zalmoxis
10 Oct 2019 ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
10 Oct 2019 Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators
10 Oct 2019 Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
10 Oct 2019 Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
10 Oct 2019 Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
10 Oct 2019 MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
10 Oct 2019 EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain
10 Oct 2019 Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
10 Oct 2019 Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer
10 Oct 2019 Bayer and RIKEN Innovation establish partnership in drug discovery
10 Oct 2019 Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
10 Oct 2019 Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
10 Oct 2019 Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
10 Oct 2019 Avacta Group plc Enters Collaboration and Option Agreement With ADC Therapeutics
10 Oct 2019 Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
10 Oct 2019 UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases
09 Oct 2019 bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
09 Oct 2019 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up